| Impact of the transition from ICD–9–CM to ICD–10–CM on the identification of pregnancy episodes in US health insurance claims data A Sarayani, X Wang, TN Thai, Y Albogami, N Jeon, AG Winterstein Clinical Epidemiology, 1129-1138, 2020 | 53 | 2020 |
| Public awareness and perception toward adverse drug reactions reporting in Riyadh, Saudi Arabia I Sales, H Aljadhey, Y Albogami, MA Mahmoud Saudi pharmaceutical journal 25 (6), 868-872, 2017 | 39 | 2017 |
| Pharmacy education in Saudi Arabia: A vision of the future H Aljadhey, Y Asiri, Y Albogami, G Spratto, M Alshehri Saudi Pharmaceutical Journal 25 (1), 88-92, 2017 | 36 | 2017 |
| Glucagon-like peptide 1 receptor agonists and chronic lower respiratory disease exacerbations among patients with type 2 diabetes Y Albogami, K Cusi, MJ Daniels, YJJ Wei, AG Winterstein Diabetes Care 44 (6), 1344-1352, 2021 | 23 | 2021 |
| Prenatal exposure to teratogenic medications in the era of Risk Evaluation and Mitigation Strategies A Sarayani, Y Albogami, TN Thai, NE Smolinski, P Patel, Y Wang, ... American journal of obstetrics and gynecology 227 (2), 263. e1-263. e38, 2022 | 19 | 2022 |
| Validation of algorithms to estimate gestational age at birth in the Medicaid analytic eXtract—quantifying the misclassification of maternal drug exposure during pregnancy Y Zhu, C Hampp, X Wang, Y Albogami, YJJ Wei, BA Brumback, ... Pharmacoepidemiology and Drug Safety 29 (11), 1414-1422, 2020 | 17 | 2020 |
| Risk of pregnancy loss in patients exposed to mycophenolate compared to azathioprine: a retrospective cohort study TN Thai, A Sarayani, X Wang, Y Albogami, SA Rasmussen, ... Pharmacoepidemiology and Drug Safety 29 (6), 716-724, 2020 | 17 | 2020 |
| Comparative effectiveness of risk mitigation strategies to prevent fetal exposure to mycophenolate A Sarayani, Y Albogami, M Elkhider, JM Hincapie-Castillo, BA Brumback, ... BMJ Quality & Safety 29 (8), 636-644, 2020 | 15 | 2020 |
| Generalizability and accuracy of IBM MarketScan health risk assessment instrument data for augmentation of commercial claims data Y Albogami, YJJ Wei, AG Winterstein Pharmacoepidemiology and drug safety 31 (1), 100-104, 2022 | 11 | 2022 |
| The safety of H1N1 vaccine in children in Saudi Arabia: a cohort study using modern technology in a developing country H Aljadhey, M Alyabsi, A Alrwisan, N Alqahtani, R Almutairi, EA Tawi, ... Drug safety 35, 555-561, 2012 | 10 | 2012 |
| Covid-19 vaccine surveillance in Saudi Arabia: opportunities for real-time assessment Y Albogami, H Alkofide, A Alrwisan Saudi Pharmaceutical Journal 29 (8), 914-916, 2021 | 8 | 2021 |
| Reproducible variability: assessing investigator discordance across 9 research teams attempting to reproduce the same observational study A Ostropolets, Y Albogami, M Conover, JM Banda, WA Baumgartner Jr, ... Journal of the American Medical Informatics Association 30 (5), 859-868, 2023 | 7 | 2023 |
| Real-world fetal exposure to acne treatments in the United States: a retrospective analysis from 2006 to 2015 Y Albogami, A Sarayani, JM Hincapie-Castillo, AG Winterstein Drug Safety 44, 447-454, 2021 | 4 | 2021 |
| Validation of algorithms to estimate gestational age in Medicaid analytic eXtract data Y Zhu, C Hampp, YJ Wei, D Roussos-Ross, B Brumback, X Wang, ... Pharmacoepidemiology and Drug Safety 26, 436-437, 2017 | 4 | 2017 |
| Evaluation of statin discontinuation stratified by primary versus secondary prevention following bariatric surgery: a retrospective cohort study A Alsuhibani, Y Albogami, V Diaby, J Friedman, SM Vouri Surgery for Obesity and Related Diseases 17 (5), 939-946, 2021 | 3 | 2021 |
| Repeat Tdap vaccination and adverse birth outcomes Y Zhu, S van Boemmel-Wegmann, Y Albogami JAMA 315 (12), 1285-1286, 2016 | 1 | 2016 |
| Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease among Type 2 Diabetes Patients: Replication and Reliability Assessment Across a Research Network M Conover, Y Albogami, J Hardin, C Reich, A Ostropolets, P Ryan | | 2024 |
| Comparing pregnancy and pregnancy outcome rates between adolescents with and without pre-existing mental disorders N Jeon, Y Albogami, SY Jung, R Bussing, AG Winterstein Plos one 19 (3), e0296425, 2024 | | 2024 |
| The effectiveness of single and two-dose Pfizer-BioNTech vaccine against SARS-COV-2: A real-world evidence from Saudi Arabia Y Albogami, A Alalwan, MA Batais, K Alabdulkareem, AA Alalwan Journal of Infection and Public Health 16 (12), 1898-1903, 2023 | | 2023 |
| Concordance of neonatal critical condition data between secondary databases: Florida and Texas birth certificate Linkage with medicaid analytic extract Y Albogami, Y Zhu, X Wang, AG Winterstein BMC Medical Research Methodology 23 (1), 47, 2023 | | 2023 |
Almut G. WintersteinProfessor for Pharmaceutical Outcomes and Policy, University of FloridaVerified email at ufl.edu
